the aid library

LIST OPTIONS

Filter

2473

Public Spending on Health: A Closer Look at Global Trends

World Health Organisation (WHO) (2018) C_WHO

The 2018 global health financing report presents health spending data for all WHO Member States between 2000 and 2016 based on the SHA 2011 methodology. It shows a transformation trajectory for the global spending on health, with increasing domestic public funding and declining external financing. T... more

Download (284)

View PDF (241)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (104)

View PDF (108)

From Panic and Neglect to Investing in Health Security

The World Bank (2017) CC

Multiple pandemics, numerous outbreaks, thousands of lives lost and billions of dollars of national income wiped out—all since the turn of this century, in barely 17 years—and yet the world’s investments in pandemic preparedness and response remain woefully inadequate. We know by now that the ... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (250)

View PDF (226)

A checklist for respiratory pathogen pandemic preparedness planning

World Health Organization WHO (2023) C_WHO

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.

Download (548)

View PDF (150)

National Guideline For Emergency Nutrition Intervention (May 2022)

Government of Ethiopia (2022) CC

Humanitarian crises exacerbate nutritional risks and often lead to an increase in acute malnutrition. Emergencies include both manmade (conflict) and natural disasters (floods, drought, cyclones, typhoons, earthquakes, volcanic eruptions, etc.). Complex emergencies are combinations of both manmade a... more

External Link

French guidelines for the management of chikungunya (acute and persistent presentations), November 2014

F.Simona,E.Javellea ,A.Cabie, et al. (2015) CC

Recommandations francaises pour la prise enc harge du chikungunya Médecine e tmaladies infectieuses 45(2015)243–263

Download (178)

View PDF (277)

WHO Information Kit on Epilepsy

World Health Organization WHO (2015) C_WHO

What you can do

Download (210)

View PDF (208)

G2. Consumo y abuso de canabis
recommended

Phillipa Hay & Jane Morris IACAPAP (2015) CC

Download (166)

View PDF (239)

Transgénero y jóvenes no conformes con su género

J. L. Turban; A. L.C. de Vries, K. J. Zucker; S. Shadianloo IACAPAP (2018) C2

Otros trastornos Capítulo H.3 Edición 2018 Edición: Matías Irarrázaval & Andres Martin Traducción: Beatriz Ortega & Macarena Espinoza

Download (137)

View PDF (219)

Lo que los profesionales de salud mental infantil deben saber sobre genética

R. R. Althoff IACAPAP (2018) C2

Introducción Capítulo A.13 Edición: Matías Irarrázaval & Andres Martin Traductores: Fernanda Prieto-Tagle & Julia Portillo

Download (346)

View PDF (296)

Trastorno de personalidad límite en adolescentes

L. Cailhol; L. Gicquel; J.-P. Raynaud IACAPAP (2018) C2

Otros trastornos Capítulo H.4 Editores: Laura Borredá Belda, Matías Irarrázaval & Andres Martin Traductores: Sara Diego Castaño, Laura Álvarez Bravos, Rebeca Santonja & Beatriz Ortega

Download (123)

View PDF (147)

Procedura per l’esecuzione di riscontri diagnostici in pazienti deceduti con infezione da SARS-CoV-2

N. Petrosillo; M. Nebuloni; M. Langer; et al. Istituto Superiore di Sanità (ISS) (2020) C2

Rapporto ISS COVID-19, n. 6/2020 Gruppo di Lavoro ISS Cause di morte COVID-19 Versione del 27 marzo 2020

Download (112)

View PDF (171)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

Download (3813)

View PDF (1374)

Logistics

R.S. Stephenson WHO; UNDP (1993)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

G2. Consumo y abuso de canabis recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

G2. Consumo y abuso de canabis
recommended